95 Startups
  • Sector
  • Participated in
  • Year of participation

2ndB

  • 2020
  • Enabling Technology
  • Venture Challenge
2ndB is creating a new preclinical in-vitro test (a brain-on-chip), capable of accurately predicting clinical efficacy, increasing the rate of success in drug development, reducing overall cost and accelerating the development of curative solutions for NDDs.

3D Lab

  • 2012
  • Enabling Technology
  • Venture Challenge
The focus in the 3D Lab is how we can use 3D technologies to improve care for each individual patient. These new technologies help improve the care and the treatment plan of patients, while taking their specific individual needs and wishes into consideration.

AgileBiotics

  • Therapeutics
  • Venture Challenge
AGILeBiotics is committed to contribute to the fight against bacterial resistance by bringing new therapeutic solutions to patients infected by multidrug resistant bacteria.

AmbAgon Therapeutics

  • 2019
  • Therapeutics
  • Venture Challenge
AmbAgon develops first-in-class small-molecule therapeutics for breast cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein.

ARTPred

  • 2013
  • Diagnostics
  • Other
It is the mission of ARTPred to make our unique technology available for all IVF patients worldwide in order to avoid unnecessary treatment burden.

Astherna

  • 2021
  • Therapeutics
  • Venture Challenge
Astherna is developing a treatment for Stargardt disease (STGD1) based on antisense oligonucleotides (AONs).

ATRO Medical

  • 2013
  • Medical Device
  • Venture Challenge
The Trammpolin® meniscus prosthesis is an anatomically shaped, non-biodegradable polymer meniscus implant designed to mimic the function of the natural meniscus and functions as a shock absorber by adequate load distribution within the knee joint.

BI/OND

  • 2016
  • Enabling Technology
  • Venture Challenge
The hardware of choice for OCC in-vitro testing of drug candidates, reducing the incidence of false positives and false negative in pre-clinical trials.

BIMINI Biotech

  • 2019
  • Therapeutics
  • Venture Challenge
BIMINI Biotech is developing therapeutic strategies for major unmet medical needs. Our first development program targets the growth hormone receptor (GHR) and its interaction with insulin-like growth factor 1 (IGF-1) for oncology, metabolic diseases and ageing.

Biomimiq

  • Enabling Technology
  • Venture Challenge
Biomimiq provides both healthy and diseased in vitro human skin equivalent for animal free compound screening and safety testing services